Chemical-Pharmaceutical Application of Carnitine Palmitoyltransferase-2 (CPT-II) Through Regulating Mitochondrial Against Cancer Tumoric Cells
Yazarlar (4)
Prof. Dr. Majıd MONAJJEMI Islamic Azad University, Central Tehran Branch, İran
Dr. Öğr. Üyesi Fatemeh MOLLAAMIN Kastamonu Üniversitesi, Türkiye
Samira Mohammadi
Islamic Azad University, Central Tehran Branch, İran
Islamic Azad University, Central Tehran Branch, İran
Sara Shahriari
Islamic Azad University, Central Tehran Branch, İran
Islamic Azad University, Central Tehran Branch, İran
| Makale Türü |
Özgün Makale
(SCOPUS dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Revista Colombiana De Ciencias Quimico Farmaceuticas Colombia | ||
| Dergi ISSN | 0034-7418 Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCOPUS | ||
| Makale Dili | İngilizce | Basım Tarihi | 01-2024 |
| Cilt / Sayı / Sayfa | 53 / 3 / 777–803 | DOI | 10.15446/rcciquifa.v53n3.119213 |
| Makale Linki | http://bucketvirtualpro-private.s3.amazonaws.com/files-bv/20241212/268970.pdf | ||
| UAK Araştırma Alanları |
Fen Bilimleri ve Matematik
|
||
| Özet |
| Background Carnitine palmitoyltransferase II deficiency is an inherited disorder of long-chain fatty acid oxidation characterized by hypoketotic hypoglycemia, cardiomyopathy, seizures, muscle pain and weakness, and myoglobin. Individuals with carnitine palmitoyltransferase II deficiency have a defect in the production of the enzyme carnitine palmitoyltransferase-II, which plays an important role in fatty acid oxidation. Signs and symptoms of carnitine palmitoyltransferase II deficiency are due to the buildup of fatty acids and long-chain acyl-carnitine as well as reduced energy production in cells. Carnitine palmitoyltransferase II deficiency is an autosomal recessive disease caused by mutations in the CPT2 gene. During changing Nonalcoholic fatty liver disease (NAFLD) to the cirrhosis, the probability of cancer is high that should be considered as a dangerous situation. Methods SDS-PAGE system of polyacrylamide gel electrophoresis through analytical method for separating charged molecules in mitochondrial mixtures according to their molecular mass in the presence of electrical fields was used. The Invitrogen® Bright Imaging (IBI) system provides was applied for the imaging and analysis of protein imprints. Results Since currently no effective treatment for CPT-II deficiency, prevention of liver failure is a proper way of treatment through controlling mitochondria without affecting CPT-II potency. We discussed about the severe infantile hepatocardiac |
| Anahtar Kelimeler |
| Carcinoma hepatocelular | carcinoma hepatocelular | CPT-I | CPT-I | CPT-I | CPT-II | CPT-II | CPT-II | Cáncer de hígado | Câncer de fígado | Doença hepática gordurosa não alcoólica | Enfermedad del hígado graso no alcohólico | Falência renal | Hepatocellular carcinoma | Insuficiencia renal | Kidny failure | Liver cancer | Nonalcoholic fatty liver disease | SDS-PAGE system | Sistema SDS-PAGE | Sistema SDS-PAGE |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Scopus | 1 |
| Google Scholar | 1 |